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Background: We have previously reported that chemicals belonging to the persistent organic pollutants (POPs)
such as perfluorinated compounds (PFAS) and polychlorinated biphenyls (PCBs) are risk factors in Breast Cancer (BC)
development in Greenlandic Inuit women. The present case–control study aimed to investigate the main effect of
polymorphisms in genes involved in xenobiotic metabolism and estrogen biosynthesis, CYP1A1, CYP1B1, COMT and
CYP17, CYP19 and the BRCA1 founder mutation in relation to BC risk and to explore possible interactions between
the gene polymorphisms and serum POP levels on BC risk in Greenlandic Inuit women.
Methods: The study population consisted of 31 BC cases and 115 matched controls, with information on serum
levels of POPs. Genotyping was conducted for CYP1A1 (Ile462Val; rs1048943), CYP1B1 (Leu432Val; rs1056836), COMT
(Val158Met; rs4680), CYP17A1 (A1> A2; rs743572); CYP19A1 (C> T; rs10046) and CYP19A1 ((TTTA)n repeats)
polymorphisms and BRCA1 founder mutation using TaqMan allelic discrimination method and polymerase chain
reaction based restriction fragment length polymorphism. The χ2 –test was used to compare categorical variables
between cases and controls and the odds ratios were estimated by unconditional logistic regression models.
Results: We found an independent association of CYP1A1 (Val) and CYP17 (A1) with BC risk.
Furthermore, an increased BC risk was observed for women with high serum levels of perfluorooctane sulfonate
(PFOS) and perfluorooctanoic acid (PFOA) and carriers of at least: one CYP1A1 variant Val allele; one variant COMT
Met allele; or the common CYP17 A1 allele. No combined effects were seen between PFAS exposure and CYP1B1
and CYP19 polymorphisms. The risk of BC was not found significantly associated with exposure to PCBs and OCPs,
regardless of genotype for all investigated SNPs. The frequency of the Greenlandic founder mutation in BRCA1 was
as expected higher in cases than in controls.
Conclusions: The BRCA1 founder mutation and polymorphisms in CYP1A1 (Val) and CYP17 (A1) can increase the
BC risk among Inuit women and the risk increases with higher serum levels of PFOS and PFOA. Serum PFAS levels
were a consistent risk factor of BC, but inter-individual polymorphic differences might cause variations in sensitivity
to the PFAS/POP exposure.
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Breast cancer (BC) is the most common cancer for
women in the western world and the incidence has been
increasing since 1940. Known established BC risk factors
include genetic inheritance e.g. mutations in the BRCA1
and BRCA2 genes, lifelong exposure to oestrogens (early
menarche and late menopause increases the risk), obes-
ity after menopause, alcohol, smoking and high intake of
fat (reviewed in [1]). Some factors seem to reduce the
risk such as low age at first birth, large number of full
term pregnancies and long duration of breastfeeding.
However, the known risk factors only explain less than a
third of all cases and the risk of BC is thought to be
modified by lifestyle and environmental exposures. Pre-
vious studies have shown that Inuit had lower incidence
of various diseases (e.g. cancer) compared to the Danish
population [2]. The incidence of BC has traditionally
been low among the Inuit, but since 1970’s a consider-
able increase has been observed in Greenland and
Canada [3,4] to a level approximately 50% of the inci-
dence in e.g. Denmark. This may suggest that changes in
lifestyle and environmental factors might be affecting
the BC risk possibly in combination with the genetic
factors [1].
Polymorphisms including single nucleotide polymor-
phisms (SNPs) in genes involved in xenobiotic metabol-
ism and in genes involved in oestrogen biosynthesis and
metabolism might affect circulating estrogen levels and
modulate the individual susceptibility to environmental
carcinogens in relation to developing BC [5]. Such can-
didate genes that have been focused on in the literature
and are included in our study are (Figure 1): cytochrome
P450 (CYP) 1A1, CYP1B1, Catechol-O-methyltransferase
(COMT), 17α-hydroxylase and 17, 20-lyase (CYP17) and
aromatase (CYP19).Figure 1 Simplified schematic presentation of enzymes involved in es
involved in metabolism of environmental chemicals. 17β-Estradiol can be me
by CYP1A1 and CYP1B1, respectively. These catecholestrogens can be cleared
4-OHE2 can be oxidised into the semiquinone, which can undergo non-enzym
estradiol; 2-OHE2: 2-hydroxyestradiol; 4-OHE2: 4-hydroxyestradiol; COMT: catecThe CYP1A1 and CYP1B1 are Phase I xenobiotic
metabolising enzymes, playing important roles in the de-
toxification of xenobiotics and metabolism of endogen-
ous steroid hormones (reviewed by [6]). CYP1A1 and
CYP1B1 catalyse the conversion of oestradiol to the 2-
OH and 4-OH catechol oestrogen metabolites (2-OH-E2
and 4-OH-E2), respectively (Figure 1). The 2-OH-E2
lacks significant oestrogenic activity whereas the 4-OH-
E2 is highly estrogenic and carcinogenic in animal
models [7] and shows increased expression in neoplastic
mammary tissue [8].
Additionally, CYP1A1 and CYP1B1 metabolically acti-
vate numerous procarcinogens including environmental
contaminants such as polycyclic aromatic hydrocarbons
(PAHs), polyhalogenated aromatic hydrocarbons (PHAHs)
(e.g. dioxin-like compounds and polychlorinated biphenyls
(PCBs) and aryl amines to reactive epoxide intermediates
that might increase the risk of oxidative stress and cancer
[6,9]. The genes are inducible by some environmental che-
micals via the aryl hydrocarbon receptor (AhR) [10,11].
Several SNPs have been identified in CYP1A1, some of
which lead to a higher inducible aryl hydrocarbon hydro-
lase (AHH) enzyme activity [9]. One CYP1A1 SNP in-
cludes the A to G transition at position 4889 in exon 7
resulting in a change from an isoleucine to valine amino
acid (Ile→Val) at codon 462 [12]. This variant is reported
to be significantly associated with CYP1A1 inducibility
and higher AHH enzyme activity [9,13] that might cause
higher rates of carcinogen activation. For CYP1B1 gene an
important SNP (C→G) at codon 432 in exon 3 leads to
an amino acid substitution of leucine to valine (Leu→
Val), which increases the 4-OH activity of CYP1B1 by 3
fold [14,15]. Due to their role in procarcinogen activation
and oxidative metabolism of oestrogens, there have been
several investigations on the association of CYP1A1 andtrogen biosynthesis and metabolism. CYP1A1 and CYP1B1 are also
tabolised into the hydroxylated catecholestrogens, 2-OHE2 and 4-OHE2
via the methylation pathway catalysed by COMT. Alternatively the
atic conversion to its quinone generating superoxide radical. E2: 17β-
hol-O-methyl transferase.
Ghisari et al. Environmental Health 2014, 13:19 Page 3 of 14
http://www.ehjournal.net/content/13/1/19CYP1B1 polymorphisms and a variety of oestrogen related
diseases e.g. BC and inconclusive results have been re-
ported [16,17].
The COMT, a phase II enzyme, methylates the cat-
echol oestrogens and convert them to their non-
genotoxic methoxy derivatives. In the COMT gene, a
single G to A base pair change results in an amino acid
change from valine to methionine (Val→Met) at codon
108 of the soluble form of COMT and codon 158 of the
membrane-bound form of COMT. This amino acid
change has been associated with 3- to 4-fold decrease in
enzyme activity in vitro [18,19]. Individuals carrying the
Met allele are hypothesised to have a decreased ability to
form the anti-tumour 2-methoxyestradiol, causing an in-
creased accumulation of the reactive catechol oestrogen
intermediates and thus facilitating the development of
oestrogen-induced tumours e.g. in BC. Epidemiological
study data on the influence of the variant COMT (Met/
Met) with human breast cancer are controversial [20,21].
The CYP17A1 gene (CYP17), codes for the cytochrome
P450c17α enzyme involved in the early stages of oestrogen
biosynthesis by catalysing the 17α-hydroxylation of preg-
nenolone and progesterone to precursors of androgen and
oestrogen, respectively (Figure 1). A common single base
pair substitution (−34 T→C) in the 5′ untranslated re-
gion (5′-UTR) of CYP17 creates an additional SP1 pro-
moter site which originally was thought to up-regulate
CYP17 transcription [22]. However, a later study did not
support this hypothesis [23] and the functional impact of
the T/C change is presently to our knowledge not known.
The common T allele is referred as A1 and the variant C
allele as A2. The rare allele A2, compared to A1, is postu-
lated to correlate with higher serum levels of various sex
steroids in some studies (e.g., testosterone, progesterone,
oestrone, and oestradiol) [22,24,25]. To date, several stud-
ies have reported the association between CYP17 poly-
morphism (−34 T→C) and BC although with conflicting
results (ref. in [26]).
The CYP19A1 (CYP19) gene encodes aromatase, the
enzyme that catalyses the final step of oestrogen biosyn-
thesis by converting androgens (testosterone and andro-
stenedione) to oestrogenic steroids (oestradiol and
oestrone) (Figure 1) [26]. Polymorphisms at this locus
may affect gene activity and thereby affect hormone
levels. Two of the polymorphisms, the tetra-nucleotide
repeat ([TTTA]n) polymorphism which varies from 7 to
13 repeats in intron 4 and a C→T single nucleotide
polymorphism (SNP) (rs10046) in the 3′-UTR of the
CYP19 gene, have been frequently studied for BC associ-
ations with inconsistent results. The variant allele of
rs10046 SNP (T) has been associated with higher levels
of postmenopausal circulating E2 [27]. The relatively
longer alleles of CYP19 (TTTA)n polymorphism such as
(TTTA)10, (TTTA)11 and (TTTA)12, have been associatedwith increased risk for development of BC in some studies
[28]. There have been reported some associations of one
or more repeats of (TTTA)8 or (TTTA)7, with higher cir-
culating oestrogens, but the results are conflicting and in-
conclusive (reviewed in [29]).
The relationship between SNPs in these genes involved
in oestrogen biosynthesis and metabolism and the risk
of BC have been investigated in different populations,
but to our knowledge no studies have been reported for
Inuit who are genetically different from Caucasians. Sev-
eral studies have reported potential interactions between
PCB concentrations and CYP1A1 gene polymorphism
associated with increased risk of BC in Caucasians
[30-32]. Studies on the gene and gene-environment
interaction on cancer risks in Greenlandic Inuit are
scarce. Therefore, we hypothesised that the risk of BC is
likely to be influenced by polymorphisms in genes re-
lated to xenobiotic and oestrogen metabolism by inter-
action with relevant environmental exposure.
The present investigation is a further analysis of our
recent BC case–control study among Greenlandic Inuit
women that examined the serum levels of persistent or-
ganic pollutants (POPs) including perfluoroalkylated
substances (PFASs), polychlorinated biphenyls (PCBs),
and organochlorine pesticides (OCPs), in relation to BC
risk [33]. An increased BC risk was observed for cases
having significantly higher serum level of PFASs and also
PCBs in the highest quartile [33].
The present study aimed to investigate polymorphism
in the genes CYP1A1, CYP1B1, COMT, CYP17 and
CYP19 in relation to BC risk and to explore possible in-
teractions between the polymorphisms and serum POP
levels on BC risk in Greenlandic Inuit women.
Methods
Study population
This study is based on our recent case–control study of
environmental exposure to POPs including PFASs and
BC risk in Greenlandic Inuit women; a detailed descrip-
tion of the study population has been reported previ-
ously [33]. Briefly, 31 BC cases (equals to 80% of all BC
cases during the sampling period 2000–2003) were
frequency-matched by age (≤50, 51–55, 56–59,≥60 yrs)
and districts of residence with controls (n = 115). All
subjects were of Greenland Inuit descent, defined as be-
ing born and having more than two grandparents born
in Greenland. The sampling period was from 2000–2003
with subjects from Nuuk, Upernavik, Qeqertarsuaq,
Narsaq, Tasiilaq, Qaqortoq, Sisimiut, Assiaat, and Nanor-
talik. Blood samples were taken when the BC was diag-
nosed. Information was collected through validated
Danish standard questionnaires and included questions
about demographic and lifestyle parameters and allowed
to document the following risk factors for BC: age,
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pause status. Furthermore, following information were
available as described [33]: plasma fatty acids, serum co-
tinine and serum oestradiol (E2).
The study was approved by Greenlandic Ethic Committee.Measurement of plasma legacy POPs and serum PFASs
As described previously [33], for cases the blood sam-
ples were taken when the BC was diagnosed, before
any treatment. The lipophilic plasma legacy POPs (12
PCB congeners and 8 OCPs), PFASs (seven PFASs in-
cluding perfluorooctane sulfonate (PFOS) and perfluor-
ooctanoic acid (PFOA)) and lipids were measured as
previously given [33]. The analyses of legacy POPs
were performed at the Centre de Toxicologie of the
Institut National de Santé Publique du Québec (Québec,
Canada) (CTQ) and PFASs were measured at the National
Environmental Research Institute, Aarhus University,
Denmark [33].
The measured PCBs and OCPs concentrations were
lipid adjusted and grouped as sum-PCBs and sum-OCPs
(μg/kg lipid). Due to difference in chemical and toxico-
logical properties of PCBs, we also conducted the ana-
lyses for dioxin-like PCBs as group, but since the results
resembled those for sum-PCBs, only the results for
sum-PCBs are given. The analysed PFASs were grouped
into perfluorosulfonated acids (sum-PFSA) and perfluor-
ocarboxylated acids (sum-PFCA) but the results resem-
bled those of PFOS and PFOA alone, respectively.
Therefore, data for sum-PFSA and sum-PFCA are not























CYP19A1 15q21.1 - (TTTA)n repeats PCR-based
BRCA1 17q21 rs80357164 Cys39Gly PCR-based
wt: wild-type; var: variant.
#TaqMan Drug Metabolism Genotyping Assay.
a432Val variant has the higher 17β-estradiol hydroxylation activity, but lower carcin
bA2 is postulated to correlate with higher serum levels of various sex steroids [22,24
cVariant alleles T has been associated with higher levels of postmenopausal circulatDNA isolation and genotyping
Genomic DNA was extracted from whole blood using
the QIAamp DNA mini Kit (Qiagen) according to the
manufacturer’s recommendations.
The following SNPs were analysed: CYP1A1 Ile462Val
(rs1048943), CYP1B1 Leu432Val (rs1056836), COMT
Val158Met (rs4680), CYP17 -34T>C (rs743572), CYP19
C > T (rs10046), CYP19 (TTTA)n repeat and BRCA1
founder mutation (p. Cys39GlY). Table 1 shows the speci-
fications of these polymorphisms. All the genotypes except
for BRCA1 and CYP19 (TTTA)n repeat were obtained
using TaqMan Drug Metabolism Genotyping Assays, fol-
lowing manufacturer’s instructions (Applied Biosystems,
ABI). The TaqMan assay was done in a 12 μL reaction vol-
ume containing 1x TaqMan Drug Metabolism Genotyping
Assay Mix (containing premixed PCR primers and MGB
probes), TaqMan Universal PCR Master mix, and 10–
15 ng genomic DNA as described previously [34]. Allele
discrimination analyses were performed on the ABI Prism
7000 Sequence Detection System. Positive controls con-
sisting of DNA representing wild-type/wild-type (wt/wt),
wt/variant and variant/variant genotypes and negative
controls (no DNA) were included in each assay.
The BRCA1 p.Cys39Gly mutation genotyping was per-
formed using allele-specific PCR amplification with
mutation-specific forward primers: BRCA1-39-N-F: 5′-
ATCAAGGAACCTGTCTCCACAAAcT-3′ (normal) and
BRCA1-39-S-F: 5′-AGGAACCTGTCTCCACAAAcg-3′
(mutation) and reverse primer BRCA1-39-fl-R: 5′-TGAC
CGGCAGCAAAATTGC TCCTGGGTTATGAAGGACA
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mixture containing 50 ng DNA, 5 μM of each forward pri-
mer and 4 μM of the reverse primer, 0.5 unit of Amplicon
Taq DNA Polymerase (Bie & Berntsen, Copenhagen,
Denmark) and 3 μl 60% sucrose. PCR conditions consisted
of an initial melting step for 5 min at 98°C followed by
30 cycles of 98°C for 30 s, 56°C for 45 s and 72°C for 45 s
(40 cycles), a final extension step at 72°C for 5 min and a
cooling phase to 14°C. The fragments were analysed using
ABI 3100: 1 μl PCR product, 0.5 μl 600 size standard and
10 μl formamid. A positive and a negative control were in-
cluded in each run.
The CYP19A1 genotyping was performed using PCR
amplification with the primers 5′- TACAGTGAGCCAAG
GTCGTG-3′ (forward) and 5′- AGTGCATCGGTATGC
ATGAG-3′ (reverse). Fifty ng of DNA in a 15 μl reaction
containing 10 μM primers, 0,1 μl Taq DNA polymerase,
1.5 μl Taq polymerase (VWR) was amplified using a touch
down PCR program. The PCR condition included a 5 min
initial denaturing step at 96°C, 19 cycles amplification
(30 s at 96°C, 30 s at 65°C (−0.5°C per cycle) and 30 s at
72°C) and 19 cycles amplification (30 s at 96°C, 30 s at
50°C and 30 s at 72°C), a 72°C extension for 5 min and
cooling phase to 14°C.
PCR products were separated on a 2.5% agarose gel
containing ethidium bromide.
The number of repeats was not confirmed by sequen-
cing. For statistical analyses, the bands on the gel were
categorised as: short (fast) = 7–10 repeats and long
(slow) = 11 and more repeats.
The most common repeats reported in the literature
are 7 (50%), 8 (10%), 11 (30%), 12 (<5%) [28].
Approximately ten percent of the samples were geno-
typed in duplicate, and when uncertainties were discov-
ered the genotyping were repeated for these samples
(very few samples).
The SNPs in CYP1A1 Ile462Val (rs1048943), CYP1B1
Leu432Val (rs1056836), COMT Val158Met (rs4680),
CYP17 -34T>C (rs743572), CYP19 C > T (rs10046),
CYP19 (TTTA)n repeat and BRCA1 were successfully
genotyped for 98%, 97%, 99%, 98%, 99%, 90% and 95% of
the total samples, respectively. Thus, the numbers re-
ported for the different polymorphisms may vary from
the total.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested for the
different genotype frequencies using the χ2 –test. The χ2 –
test or Fisher’s exact tests were used to compare cate-
gorical variables between cases and controls (allele and
genotype frequencies, smoking status, breastfeeding etc.).
Fisher’s exact test was also used to compare the genotype
differences in the dominant model: common, wild-type
(wt) homozygous (CYP1A1: Ile/Ile; CYP1B1: Leu/Leu;COMT: Val/Val; CYP17: A1A1; CYP19 C > T: CC; CYP19
TTTA: (TTTA)<10) vs. those with at least one variant (var)
allele (CYP1A1: Ile/Val + Val/Val; CYP1B1: Leu/Val + Val/
Val; COMT: Val/Met +Met/Met; CYP17: A1A2 +A2A2;
CYP19 C >T: CT +TT; CYP19 TTTA: (TTTA)≥10).
Unconditional logistic regression analysis was used to
estimate odds ratios (ORs) and 95% confidence intervals
(CI) for the association between SNPs and BC, and the
interaction between SNPs, POP variables and BC risk.
For SNP analyses, genotypes were coded as counts of
the risk allele (wt/wt = 0; wt/var = 1 and var/var = 2) and
the homozygous common (wt/wt) genotype was used as
reference group. The genotyping data were also cate-
gorised into two groups (dominant model): homozygous
common (wt/wt; referent) and heterozygous + homozy-
gous variant alleles (wt/var + var7var). The heterozygous
and homozygous variant alleles were combined in order
to ensure sufficient sample size for comparisons.
For the association between SNPs and BC, the model
was adjusted for age and serum cotinine as continuous
variables, since smoking can affect the gene expression
of some of the CYP450 genes [9]. We also conducted
stratified analysis to see if the association with SNPs var-
ied by menopausal status. Menopausal status was un-
known for 36 of the samples (11 cases and 26 controls):
among these, 31 women were between 18–42 years old
and 5 women between 66–80 years old [33]. In this
study, women who had missing information on meno-
pausal status were designated premenopausal if they
were between 18–42 years old, and considered postmen-
opausal if they were between 66–80 years old.
The POP variables were natural logarithmic trans-
formed to improve the normality and homogeneity of
variance and thus the analyses were performed on the
ln-transformed POP data.
For the interaction between SNPs and POP exposure
the model was adjusted for age and cotinine and not
with additional factors (e.g. BMI, total number of full-
term pregnancies, breastfeeding and menopausal status)
since the number of cases are too few and because these
factors are not real confounders and cannot affect the
genotype. The POP variables (PFOS, PFOA, sum-PFSA,
sum-PFCA, Sum-PCBs and sum-OCPs) were cate-
gorised as “low” or “high” based on the corresponding
median values of control group. Additionally, these ana-
lyses were conducted with ln-transformed POP data as
continuous variables. Women with the homozygous
common genotypes and the lowest level of exposure to
POPs were used as reference group in the analyses of
the relation between SNPs, POPs and BC risk, respect-
ively. For the interactions between genotypes and POP
variables we also included the cross-product terms in
the logistic regression models and assessed the Wald test
statistic for these interaction terms.
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statistical software (SPSS Inc., Chicago, IL, USA). A two-
sided P value ≤ 0.05 was considered statistically signifi-
cant in the analyses.
Results
The demographic and baseline characteristic of the
study population and the effects of POPs on BC risk
have been previously reported [33] (see Additional file 1:
Table S1). There were no significant differences among
cases and controls in terms of median age, BMI and
menopausal status. BC cases compared to their controls
had lower number of full term pregnancies and serum
cotinine level which reflects the current smoking status
of the subjects.
Allele and genotype frequencies in Greenlandic Inuit
women and relationship with BC
Previously, we reported for the first time allele and
genotype frequencies of CYP1A1 Ile 264Val, CYP1B1
Leu432Val and COMT Val158Met polymorphisms in
Greenlandic Inuit [34]. The allelic frequencies of the
CYP17 -34T>C (rs743572), CYP19 C > T (rs10046) and
CYP19 (TTTA)n repeat have not been previously pub-
lished for Inuit population.
Table 2 shows the genotype frequencies and allelic dis-
tribution of all studied SNPs in this study. For all SNPs,
the genotype frequencies for both cases and controls
were in HWE, with p values in the range 0.16 - 0.89 (not
shown). In general for Greenlandic Inuit (control group),
the frequency of CYP1A1 Val variant allele was 47.8%;
CYP1B1 Val variant allele 14.9%, COMT low activity
Met allele 59.7%; CYP17 A2 allele 53.5%; CYP19 C > T
variant T allele 18.0%; CYP19 TTTA(11–13) 13.9% and
the frequency of the BRCA1 founder mutation was 1.4%.
We compared the distribution of the SNPs between
cases and controls and the association to BC (in models
adjusted for age and cotinine) (Table 2). The χ2 tests for
distribution showed no significant differences between
cases and controls in most of the genotype frequencies
except for borderline significant differences in CYP17
-34T>C (A1> A2) between cases and controls. The pres-
ence of at least one CYP17 A2 variant allele (A1/A2 +
A2/A2) was borderline significant lower in cases (60% in
cases vs. 79% in controls; p = 0.054). Although not sig-
nificantly, the BC cases tend to have higher frequency of
the CYP1A1 variant Val allele (57% in cases vs. 48% in
controls), lower frequency of the CYP1B1 variant Val al-
lele (9.7% in cases vs. 15% in controls), lower frequency
of the CYP19 (C> T) variant T allele (13% vs. 18%) and
lower frequency of the CYP19 (TTTA) ≥10 allele (6.5%
vs. 14%). We observed a strong correlation between long
alleles of the CYP19 (TTTA)n polymorphism and the
CYP19 T allele of rs10046 SNP: The longer (TTTA)nallele was significantly more common in individuals with
the T allele of rs10046 SNP (rs = 0.79; p < 0.0001).
In unconditional logistic regression analysis, we found
that women with at least one CYP1A1 variant Val allele
(Ile/Val + Val/Val) had a significantly increased risk of
BC (adjusting for age + cotinine) compared to women
with the common homozygous Ile/Ile genotype as refer-
ence (adjusted OR: 4.35; 95% CI: 1.08-17.4; p = 0.038)
(Table 2).
Compared to women with the common homozygous
A1/A1 genotype a significantly lower risk of BC was ob-
served among women with at least one variant CYP17
A2 allele (adjusted OR: 0.34; 95% CI: 0.12-0.94; p =
0.038) (Table 2). Upon adjustment for age and cotinine
the OR was still nearly the same and significant.
Compared to controls, the BRCA1 founder mutation
allele was overrepresented among BC cases (cases: 4.8%
vs. controls: 1.4%) and women with the BRCA1 founder
mutation had a non-significant (because of low num-
bers) elevated risk of developing BC compared to those
without this mutation (adjusted OR: 5.14; 95% CI: 0.45-
58.87; p = 0.189). Adjusting for age and cotinine in-
creased the OR to 5.14 (Table 2).
Further analyses by stratification by menopause status
showed among premenopausal women a significant as-
sociation between CYP1A1 variant Val allele and BC risk
(OR: 5.180, 95% CI: 1.0-26.5) (Table 3). In addition,
among premenopausal women a significant inverse asso-
ciation between the CYP1B1 variant Val allele and BC
risk was observed (OR: 0.115, 95% CI: 0.01-1.00; p =
0.05). For the other genes no differences in ORs were
seen between the strata of menopause status.
Combined effect of polymorphism and serum POPs
Recently, we reported significant positive associations
between serum levels of total PCBs and PFASs and BC
in Greenlandic Inuit women for the same study group
[33]. The BC cases had significantly higher concentra-
tions of PFASs and also PCBs in the highest quartile, in-
dicating that the level of serum PFASs and PCBs might
be risk factors in the development of BC in Inuit.
The association between serum levels of PFASs and
legacy POP variables (PCBs and OCPs) and risk of BC
in Inuit women was evaluated after stratification by ge-
notypes for the assessment of gene–environment inter-
action (Table 4) as well as using the POP data as
continuous variables (see Additional file 1: Table S2).
In general, high serum PFAS levels (above the median
distribution in the control group), increased the BC risk
in all the genotype strata considered, indicating that
PFAS exposure was a consistent risk factor for BC.
The risk of BC was not significantly associated with
exposure to PCBs and OCPs, regardless of genotype for
all investigated SNPs. This risk of BC associated to high
Table 2 Distribution of genotypes and the relationship between polymorphisms of studied genes and the risk of female





P (χ2) Odds ratio (95% CI); p-value
Crude Age adjusted Age and cotinine adjusted
CYP1A1
(Ile462Val)
Ile/Ile 4 (13.3) 32 (28.3) .241* 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Ile/Val 17 (56.7) 54 (47.8) 2.52 (0.78-8.15); p = 0.123 2.52 (0.78-8.14); p = 0.124 5.08 (1.19-21.6); p = 0.028
Val/val 9 (30.0) 27 (23.9) 2.67 (0.74-9.63); P = 0.134 2.66 (0.73-9.67); p = 0.138 3.31 (0.69-15.9); p = 0.135
Ile/val + Val/val 26 (86.7) 81 (71.7) .104** 2.57 (0.83-7.95); P = 0.102 2.56 (0.83-7.95); p = 0.103 4.35 (1.08-17.5); p = 0.038
Val allele 35 (58.3) 108 (47.8)
CYP1B1
(Leu432Val)
Leu/Leu 26 (83.9) 79 (71.2) .159 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Leu/val 4 (12.9) 31 (27.9) 0.39 (0.13-1.21); p = 0.105 0.39 (0.13-1.22); p = 0.105 0.39 (0.094-1.45); p = 0.174
Val/val 1 (3.2) 1 (0.9) 3.04 (0.18-50.3); p = 0.438 3.03 (0.18-50.1); p = 0.439 -
Leu/val + Val/val 5 (16.1) 32 (28.8) .174 0.48 (0.17-1.35); p = 0.161 0.47 (0.17-1.34); p = 0.160 0.39 (0.094-1.45); p = 0.174
Val allele 6 (9.7) 33 (14.9)
COMT
(Val158Met)
Val/val 7 (22.6) 19 (16.8) .504 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Val/Met 11 (35.5) 53 (46.9) 0.56 (0.19-1.66); p = 0.299 0.56 (0.19-1.67); p = 0.300 0.65 (0.19-2.16); p = 0.476
Met/met 13 (41.9) 41 (36.3) 0.86 (0.29-2.53); p = 0.783 0.87 (0.29-2.56); P = 0.871 0.65 (0.19-2.26); p = 0.498
Val/Met-Met/Met 24 (77.4) 94 (83.2) .441 0.69 (0.26-1.84); p = 0.461 0.69 (0.26-1.85); P = 0.463 0.65 (0.22-1.93); p = 0.435
Met allele 37 (59.7) 135 (59.7)
CYP17
(−34 T > C)
TT (A1/A1) 12 (40) 24 (21.2) .107 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
TC (A1/A2) 12 (40) 57 (50.4) 0.41 (0.16-1.05); p = 0.062 0.40 (0.16-1.03); p = 0.057 0.35 (0.12-1.05); p = 0.06
CC (A2/A2) 6 (20) 32 (28.3) 0.36 (0.12-1.10); p = 0.073 0.35 (0.11-1.03); p = 0.067 0.25 (0.063-0.95); P = 0.042
A1/A2 + A2/A2 18 (60) 89 (78.8) .054 0.39 (0.16-0.93); p = 0.033 0.38 (0.16-1.04); p = 0.030 0.34 (0.12-0.94); P = 0.038
A2 allele 24 (40) 121 (53.5)
CYP19
(C > T)
CC 23 (74.2) 79 (69.3) .424 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
CT 8 (25.8) 29 (25.4) 0.95 (0.38-2.36); p = 0.908 0.94 (0.38-2.35) p = 0.944 1.29 (0.45-3.71); p = 0.639
TT 0 (0) 6 (5.3) - - -
CT + TT 8 (25.8) 35 (30.7) .662 0.79 (0.32-1.95); p = 0.608 0.78 (0.32-1.93); P = 0.594 1.13 (0.39-3.23); p = 0.821
T allele 8 (12.9) 41 (18)
CYP19
(TTTA)n
F (7–10) 27 (87.1) 76 (75.2) .317 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
SF 4 (12.9) 22 (21.8) 0.51 (0.16-1.62); p = 0.255 0.50 (0.16-1.58); p = 0.236 0.70 (0.2-2.45); p = 0.577
S (11–13) 0 (0) 3 (3.0) - - -
SF + S 4 (12.9) 25 (24.8) .217 0.45 (0.14-1.41); p = 0.17 0.44 (0.14-1.39); p = 0.160 0.70 (0.20-2.45); p = 0.577
S allele 4 (6.5) 28 (13.9)
BRCA1
(Cys39Gly)
Cys/Cys 28 (90.3) 106 (97.2) .122 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)
Cys/Gly 3 (9.7) 3 (2.8) 3.79 (0.73-19.7); p = 0.115 4.29 (0.77-23.9); p = 0.097 5.14(0.45-58.9); p = 0.189
Gly /Gly 0 (0) 0 (0)
Gly allele 3 (4.8) 3 (1.4)
*p-value for comparison between the 3 genotypes (wt/wt; wt/var; var/var) using chi-2 analysis.
**p-value for comparison between the wt/wt and wt/var+var/var (dominant model).
Boldface indicate significance at p<0.05.
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fold in women with at least one variant CYP1A1 Val al-
lele compared to women homozygous for the common
Ile allele. The same association was found for COMT,
where the presence of at least one variant COMT
Met allele, and high PFOS and PFOA serum levelssignificantly increased the ORs of BC risk. Further-
more, women with the common CYP17 A1 allele and
high levels of PFOS had higher risk for BC compared
to women homozygous for the variant A2 allele. The
risk of BC associated with PFOA was higher and sig-
nificant among women with at least one CYP17 A2 allele
Table 3 Logistic regression stratified by menopause status for relationship between polymorphisms and the risk of






OR* 95% CI (Ca/Co) N OR* 95% CI
CYP1A1
(Ile/Ile vs Ile/Val + Val/Val)
2/17 vs 14/25 5.18 1.01 26.5 0.048 2/15 vs 12/56 1.47 0.28 7.65 0.65
CYP1B1
(leu/Leu vs Leu/Val + Val/Val)
16/28 vs 1/13 0.12 0.013 1.00 0.050 10/52 vs 4/19 1.56 0.40 6.09 0.52
COMT
(Val/Val vs Val/Met + Met/Met)
3/8 vs 14/34 1.19 0.27 5.28 0.82 4/11 vs 10/60 0.53 0.13 2.20 0.38
CYP17
(A1/A1 vs A1/A2 + A2/A2)
7/11 vs 9/31 0.42 0.12 1.43 0.16 5/12 vs 9/57 0.47 0.12 1.85 0.28
CYP19 (C > T)
(CC vs CT + TT)
13/31 vs 4/11 0.79 0.21 3.04 0.74 10/48 vs 4/24 0.94 0.24 3.60 0.93
CYP19 (TTTA)n
(F/F vs F/S + S/S)#
14/33 vs 3/7 0.95 0.21 4.27 0.94 13/43 vs 1/18 0.21 0.025 1.79 0.15
Ca: case, Co: control.
*Adjusted for age but not cotinine because of small sample size.
#F: 7–10 TTTA repeats; S: 11–13 TTTA repeats.
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A1 variant.
After stratification by CYP1B1 genotype, no cases were
observed among those with low PFAS levels and carrier
of at least one variant CYP1B1 Val allele, and therefore
the ORs could not be determined. However, when the
group (including case and controls) with the common
CYP1B1 Leu/Leu genotype and low PFAS level was used
as reference group instead, the ORs were the same for
individuals with high PFAS exposure regardless of their
CYP1B1 genotype (Leu/Leu versus Leu/Val + Val/Val)
(not shown). Similarly, the genotype status of the CYP19
C > T SNP did not change the risk of BC associated to
high PFASs (Table 4).
Despite the different risk of BC associated to PFOS/
PFOA in different strata of gene polymorphisms we did
not found a significant interaction between the PFASs
variables and gene polymorphisms, when introducing
the interaction terms into the model.
Discussion
In the present case–control study of BC, six SNPs in key
genes involved in xenobiotic metabolism as well as in
oestrogen synthesis and metabolism and BRCA1 founder
mutation were genotyped to explore the possible rela-
tionship of these polymorphisms in the development of
BC in Greenlandic Inuit women.
Additionally, we evaluated the potential combined ef-
fects of these SNPs and environmental contaminant ex-
posure. Our results showed higher tendency of BRCA1
founder mutation in cases than in controls and signifi-
cant associations between BC and SNPs in CYP1A1 and
CYP17. Generally, high serum PFAS levels was a consist-
ent risk factor of BC, and in combination with having atleast one variant CYP1A1 Val allele, or one variant
COMT Met allele, or the common CYP17 A1 allele, the
PFAS-associated BC risk increased, indicating that these
polymorphisms can act as modulators of the develop-
ment of BC related to environmental exposure.
Mutations in BRCA1 and BRCA2 are responsible for a
large proportion of hereditary BC which account for ap-
proximately 8-10% of BC cases [35]. In the present
study, BC cases had a higher frequency of the Green-
landic BRCA1 founder mutation compared with their
controls (4.8% in cases vs. 1.4% in controls; Table 2);
however, the BRCA1 mutation alone could not explain
the frequency of BC cases in our study population. In
the general Greenlandic population, the overall carrier
frequency of BRCA1 founder mutation is 1.6%, but the
frequency differs geographically from 0.6% at the West
coast to 9.7% in the previously isolated populations at
the East coast [36].
High and prolonged exposure to oestrogens plays a
central role in breast carcinogenesis, by stimulating cell
growth through oestrogen receptor pathway and by for-
mation of genotoxic and mutagenic metabolites [37].
Therefore, functional SNPs which can change the levels
of oestrogen or its metabolite have been extensively in-
vestigated in different populations, and controversial
data are reported. Several factors might explain the con-
troversy, such as interaction with other know BC risk
factors, difference in polymorphism modifying the sus-
ceptibility of different ethnic groups to e.g. exposure to
environmental contaminants. Inuit are genetically differ-
ent from Caucasians in several genes [34,38] being more
similar to East Asians, like Chinese. Moreover, Arctic
Inuit e.g. Greenlandic have some of the highest exposure
and thus body burden of environmental contaminants
Table 4 Odds ratios of breast cancer and 95% confidence intervals associated with PFOS and PFOA among breast






Age + cotinine adjusted
p
OR 95% CI OR 95% CI OR 95% CI
CYP1A1 PFOS
Ile/Ile Low 1/17 1 (Ref) 1/17 1 (Ref) 0/17 1 (Ref)
Ile/Ile high 3/11 4.64 0.43-50.4 .208 3/11 6.33 0.35-114.1 .211 3/11
Ile/Val + Val/Val Low 2/32 1 (Ref) 2/32 1 (Ref) 2/32 1 (Ref)
Ile/Val + Val/Val High 24/36 10.67 2.34-48.7 .002 24/36 12.4 2.57-59.9 .002 20/36 12.1 1.29-115 .029
CYP1B1
Leu/Leu Low 3/28 1 (Ref) 3/28 1 (Ref) 2/28 1 (Ref)
Leu/Leu High 23/38 5.6 1.5-20.7 .009 23/38 7.3 1.80-29.4 .005 20/38 11.2 1.8-71.1 .011
Leu/val + Val/Val Low 0/20 1 (Ref) 0/20 1 (Ref) 0/20 1 (Ref)
Leu/val + Val/Val High 5/8 0 (12.5) 5/8 4/8
COMT
Val/Val Low 1/9 1 (Ref) 1/9 1 (Ref) 0/9 1 (Ref)
Val/Val High 6/8 6.75 0.66-68.8 .107 6/8 7.13 0.65-77.6 .107 5/8
Val/Met + Met/Met Low 2/40 1 (Ref) 2/40 1 (Ref) 2/40 1 (Ref)
Val/Met + Met/Met High 22/39 11.28 2.48-51.2 .002 22/39 15.36 3.02-78.2 .001 19/39 16.8 1.68-167 .016
CYP17
A1/A1 Low 0/12 0/12 0/12
A1/A1 High 10/12 10/12 10/9
A1/A2 + A2/A2 Low 3/37 1 (Ref) 3/37 1 (Ref) 2/37 1 (Ref)
A1/A2 + A2/A2 High 15/37 5.00 1.34-18.7 .017 15/37 5.67 1.38-23.4 .016 13/36 18.2 1.67-198.8 .017
CYP19_CT
CC Low 3/34 1 (Ref) 3/34 1 (Ref) 1/33 1 (Ref)
CC High 20/29 7.86 2.11-29.2 .002 20/29 8.85 2.15-36.4 .003 14/27 9.6 1.48-62.4 .018
CT + TT Low 0/15 0/15 0/15
CT + TT High 8/19 8/19 8/19
CYP19_TTTA
(TTTA)8–10 Low 3/35 1 (Ref) 3/35 1 (Ref) 2/35 1 (Ref)
(TTTA)8–10 High 24/29 9.66 2.64-35.3 .001 24/29 8.92 2.33-34.2 .001 20/29 29.3 2.89-298 .004
(TTTA)11–13 Low 0/11 0/11 0/11
(TTTA)11–13 High 4/13 4/13 4/12
Ile/Ile Low 1/15 1 (Ref) 1/15 1 (Ref) 1/15 1 (Ref)
Ile/Ile High 3/13 3.46 0.32-37.5 .307 3/13 4.26 0.24-75.3 .322 3/13 10.5 0.12-907 .303
Ile/Val + Val/Val Low 6/33 1 (Ref) 6/33 1 (Ref) 5/33 1 (Ref)
Ile/Val + Val/Val High 20/35 3.14 1.12-8.79 .029 20/35 3.30 1.13-9.7 .030 17/35 3.58 0.81-15.8 .092
CYP1B1
Leu/Leu Low 8/27 1 (Ref) 8/27 1 (Ref) 6/27 1 (Ref)
Leu/Leu High 18/39 1.6 0.59-4.10 .369 18/39 1.6 0.56-4.70 .351 16/39 2.1 0.59-7.6 .25
Leu/val + Val/Val Low 0/20 1 (Ref) 0/20
Leu/val + Val/Val High 5/8 0 (12.5) 4/8
COMT
Val/Val Low 3/8 1 (Ref) 3/8 1 (Ref) 2/8 1 (Ref)
Val/Val High 4/9 1.19 0.20-6.99 .851 4/9 1.15 0.19-6.87 .882 3/9 8.32 0.29-235 .215
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Table 4 Odds ratios of breast cancer and 95% confidence intervals associated with PFOS and PFOA among breast
cancer patients and controls (Continued)
Val/Met + Met/Met Low 5/40 1 (Ref) 5/40 1 (Ref) 4/40 1 (Ref)
Val/Met + Met/Met High 19/39 3.89 1.32-11.5 .014 19/39 4.68 1.42-15.5 .011 17/39 3.73 0.86-16.3 .080
CYP17
A1/A1 Low 3/10 1 (Ref) 3/10 1 (Ref) 2/10 1 (Ref)
A1/A1 High 9/12 2.50 0.53-11.8 .247 9/12 2.35 0.45-12.2 .309 8/12 0.84 0.093-0.60 .877
A1/A2 + A2/A2 Low 4/38 1 (Ref) 4/38 1 (Ref) 3/38 1 (Ref)
A1/A2 + A2/A2 High 14/36 3.69 1.11-12.3 .033 14/36 4.00 1.10-14.5 .035 12/36 8.79 1.22-63.5 .031
CYP19_CT
CC Low 7/32 1 (Ref) 7/32 1 (Ref) 5/32 1 (Ref)
CC High 16/31 2.36 0.85-6.55 .099 16/31 2.21 0.705-6.95 .173 13/31 2.44 0.57-10.4 .227
CT + TT Low 1/16 1 (Ref) 1/16 1 (Ref) 1/16 1 (Ref)
CT + TT High 7/18 6.22 0.69-56.2 .104 7/18 7.18 .737-67.0 .090 7/18 4.99 0.34-74.7 .244
CYP19_TTTA
(TTTA)8–10 Low 8/33 1 (Ref) 8/33 1 (Ref) 6/33 1 (Ref)
(TTTA)8–10 High 19/31 2.53 0.97-6.61 .058 19/31 2.07 .753-5.71 .158 16/31 3.28 0.74-14.6 .119
(TTTA)11–13 Low 0/12 1 (Ref) 0/12 1 (Ref) 0/12 1 (Ref)
(TTTA)11–13 High 4/12 0 4/12 4/12
Ca: case, co: control.
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reported for Inuit on gene polymorphisms, gene-
environment interaction for genes involved in xenobiotic
and oestrogen metabolism and associations with cancer
risk.
In the present study, we report for the very first time
the allelic frequencies of CYP17 -34T>C, CYP19 T > C
and CYP19 (TTTA)n repeat in Greenlandic Inuit
women, and previously we did report the allelic distribu-
tion of CYP1A1 Ile 264Val, CYP1B1 Leu432Val and
COMT Val158Met polymorphisms in Greenlandic Inuit
[34]. The frequency of the CYP17 -34T>C A2 allele
(54%) in the present study was similar to those reported
for Chinese (56%) [39], but higher than those reported
for Japanese (43%) and Caucasians (37% in UK) [40].
The frequency of the CYP19 C > T variant T allele in the
Inuit control group (18%) was relatively low and differ-
ent from those reported for other populations such as
Chinese and Caucasians (46%); but more similar to
African-American (26.2%) [41]. For CYP19 (TTTA)n re-
peat we observed higher proportion of shorter repeats
relative to higher repeats in line with what has been re-
ported for Asians [28].
The CYP1A1 Ile462Val polymorphism was independ-
ently associated with increased risk of BC and signifi-
cantly upon adjustment for current smoking (cotinine).
It has been suggested that individuals with the CYP1A1
variant Val allele having increased inducibility and AHH
enzymatic activity may produce more carcinogenicmetabolites and thus more susceptible to developing BC.
In Caucasians the variant CYP1A1 Val/Val genotype was
suggested to be associated with a higher risk of BC [17],
whereas in Chinese and Japanese this amino acid substi-
tution was associated with other types of cancer, as lung
cancer [42]. Several studies have shown a significant as-
sociation between the CYP1A1 polymorphism and BC
risk only in smokers [43,44], which could be related to
the reported increase in inducibility of CYP1A1 poly-
morphism in smokers [9]. However, the association to
BC was not seen in all women, suggesting that the vari-
ant CYP1A1 allele affects the BC risk by modifying the
metabolism of the environmental carcinogens rather
than oestrogens. In addition, based on in vitro data sug-
gesting that variant forms of CYP1A1 are more indu-
cible by PCBs, it has been hypothesised that there could
be a combined effect between PCB levels and the variant
CYP1A1 Val polymorphisms and increased BC risk. Pre-
viously it was reported a significantly increased post-
menopausal BC risk, among women with high serum
PCB levels (above the median for the control group) and
with at least one Val allele [31]. Other studies have re-
ported that the BC risk was significantly elevated among
women with high PCB levels and the variant CYP1A1
polymorphisms who had ever smoked but not for those
who had never smoked [30,31]. Another mode of action
for PCBs was suggested e.g. the metabolism of PCBs by
CYP1A1 to produce free radical and subsequently oxida-
tive DNA damage in breast tissue [45].
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Greenlandic Inuit women exposed to high serum PCB
levels, but for exposure to PFASs including PFOS. In our
study population, the presence of the CYP1A1 Val allele
increased the risk of BC associated to PFASs/PFOS. It is
unknown whether PFOS, like some PCBs, is able to in-
duce CYP1A1 gene via AhR that might lead to activation
of procarcinogenic compounds and also oxidative me-
tabolism of oestrogens [32]. PFOS and PFOA were re-
ported to increase the CYP1A1 expression in salmon
kidney and liver [46], and PFOS significantly further in-
creased the TCDD-induced AhR activity in rat Hepa-
toma cells [47]. Recently, we also investigated the effect
of seven PFASs on AhR, and found that only PFDoA
and PFDA did transactivate AhR in mouse Hepatoma
cells [48]. The effect of PFASs in human cells is un-
known and warrants further investigation. Therefore, it
seems biological plausible that there can be an inter-
action between CYP1A1 and PFASs on the risk of BC.
Future studies are needed to confirm our data for Inuit
women.
Many studies have investigated the effects of CYP1B1
polymorphisms in modifying BC risk [16], due to its role
in production of 4-OH-E2, a potential carcinogenic es-
trogen metabolite, and the activation of a number of en-
vironmental carcinogens. Associations between the
CYP1B1 Leu432Val polymorphism and BC risk seems to
be race-specific as the homozygous variant CYP1B1 Val/
Val genotype has been associated with BC in Caucasian
women [49], while the wild type Leu/Leu genotype was
associated with BC in Chinese postmenopausal women
[50]. In Inuit population the Val/Val genotype was rare
(under 1% for the control group). Although not signifi-
cantly, Inuit BC cases had higher frequency of Leu/Leu
compared to their controls, which is consistent with the
results observed for Chinese women [50]. The amino
acid change from Leu to Val increases the 4-OH enzyme
activity of the CYP1B1 [51], whereas the AHH activity
to form reactive metabolites from procarcinogens (e.g.
PAHs and heterocyclic aryl amines) was shown to be
slightly higher in the Leu432 form [14]. Therefore, it is
plausible that Leu/Leu carriers exposed to high concen-
trations of POPs are consequently exposed to more re-
active metabolites and thus more at risk for BC.
The cellular balance between phase I and phase II en-
zymes can be critical for the susceptibility to exposure to
E2 cathechol metabolites. Many epidemiological studies
have investigated the association of the phase II COMT
variant (Met/Met) with BC, but the results are inconclu-
sive [20,21]. Although most studies showed no associ-
ation, some studies did find significant associations
between the variant COMT Met allele and risk of BC
[21]. In our study we did not observe any significant as-
sociation to COMT Val158Met polymorphism. Humanstudies have suggested that high levels of CYP1B1 ex-
pression and low levels of COMT expression in adjacent
non-tumour tissue were associated with an increased
risk of BC [52] and other E2-responsive cancers [53,54].
However, it is also conceivable to speculate that a com-
bination of a low-activity CYP1B1 (carrying the 432Leu
allele) with a high activity COMT (carrying the common
158Val allele) may play a protective role for Inuit, since
it might result in lower levels of catechol oestrogen and
the subsequent oxidative damage in the cells. A study in-
vestigating the combined effect of high-risk genes for
CYP1B1, COMT, glutathione S-transferase pi (GSTP1)
and manganese superoxide dismutase (MnSOD) on BC
risk in Caucasian postmenopausal women reported that
the presence of both the CYP1B1 high activity Val and
COMT low activity Met was associated with an in-
creased risk of BC (OR 2.0, 95% CI 1.1–3.5) [55]. We
also attempted to analyse the combined effect of the
genes on BC risk, but did not get any significant results,
which might be explained by the limited size of our
study and the low frequency of CYP1B1 Val carriers, or
different of ethnicity.
Among the Greenlandic Inuit women, the CYP17 vari-
ant A2 allele was associated with decreased risk of BC.
A2 variant of CYP17 rs743572 SNP has been postulated
to cause differences in circulating hormone levels and
possibly influence the risk of BC [22,24,25]. However,
these findings were not supported by other studies
[27,56,57]. In postmenopausal Chinese women the
CYP17 A1/A2 genotype was found to associate with in-
creased risk of BC [39] compared with A1/A1 genotype.
Similar to our result, in a Finnish population a tendency
of lower risk of BC risk was found for premenopausal
women carrying at least one CYP17 A2 allele [58].
CYP17 A2 was also reported to inversely associate with
endometrial cancer risk among “Nurses’ Health Study”
cohort [59]. A Meta analyses showed that, although not
significantly, A2 was positively associated with risk of
BC in post-menopausal women, but inversely related to
BC in pre-menopausal women [60]. In contrast, two
other Meta analyses found no association between A1 or
A2 allele and BC risk [61]. In our study the risk of BC
associated with CYP17 polymorphism was the same for
pre- and postmenopausal women.
The CYP19 activity determines the local oestrogen
level and it is biologically reasonable to hypothesis that
variations in this gene can result in different expression
or change in aromatase activity, which can affect
oestrogen levels. In the current study, we found no sig-
nificant BC risk associated to the two investigated poly-
morphisms in CYP19 gene ((TTTA)n and rs10046).
However, we observed a tendency for inverse association
for longer repeats (TTTA)11–13 with BC risk, supported
by a meta-analysis restricted to Asians (OR = 0.752, 95%
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ther investigated in a larger study group among Inuit.
The CYP19 T variant (CT + TT) in rs10046 polymorph-
ism has been associated to BC risk in some studies
including Asians [39]. However, in our study the occur-
rence of the T allele was lower among cases. Moreover,
the frequency of the T allele in the Inuit control group
(18%) was much lower than those reported for Asians
and Causations. We cannot give or find any explanation
for this finding.
Generally, high serum PFAS levels was a consistent
risk factor of BC in this study population and higher
levels of PCBs were also found in BC cases [2]. As dis-
cussed in our previous paper [2], several in vivo and
in vitro studies have indicated that PFASs may have the
potential to disrupt endocrine homeostasis. In vivo stud-
ies have reported decrease in thyroid hormone and in-
crease in oestradiol levels after exposure to PFASs
including PFOS and PFOA (reviewed in [62]). Our re-
cent in vitro data showed that PFOS, PFOA and PFHxS
significantly induced the ER transactivity in human
MVLN breast carcinoma cells [63] and several PFASs in-
cluding PFOS and PFOA antagonised the thyroid
hormone-induced GH3 cell proliferation (T-screen
assay) [48]. PFOS and PFOA were also found to induce
the proliferation of human MCF-7 BOS breast cancer
cells in the E-screen assay [64] and to induce the
estrogen-responsive biomarker protein vitellogenin in ju-
venile rainbow trout [65]. Future studies are needed to
understand the possible roles of PFASs as endocrine dis-
rupters on sex hormone homoeostasis and function and
their role in breast cancer patogenesis.
A limitation of our study is the small sample size and
thus the statistical power for the detection of subtle
changes might be relatively weak. Because of the low
population size in Greenland (approximately 57.000) the
number of BC cases during the sampling time was rela-
tively low although the cases in this study comprise 80%
of all the cases detected during this period. Therefore,
our results should be interpreted with caution and there
is a need for larger study group to confirm our results.
Most previous reports found that the effect of low-
penetrance polymorphisms of individual gene on the risk
of breast cancer was minor. This is not fully surprising
since breast cancer is a multifactorial disease that in-
volves interaction between multiple genetic and environ-
mental events. However, larger population studies are
needed to detect statistical evidence for gene–gene and
gene–environment interactions.
Conclusions
In conclusion, our results suggest that polymorphisms in
CYP1A1 (Val) and CYP17 (A1) are associated with in-
creased BC risk among Inuit women and this risk isincreased in women having higher serum levels of PFASs
(PFOS/PFOA). Serum PFAS levels were a consistent risk
factor of BC, but inter-individual polymorphic differ-
ences might cause variations in sensitivity to the effects
of these POPs as a potential cause of BC in Inuit.
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